ISBN: 9780262329859 | 320 pp. | September 2015


Translational Neuroscience

Toward New Therapies
Today, translational neuroscience faces significant challenges. Available therapies to treat brain and nervous system disorders are extremely limited and dated, and further development has effectively ceased. Disinvestment by the private sector occurred just as promising new technologies in genomics, stem cell biology, and neuroscience emerged to offer new possibilities. In this volume, experts from both academia and industry discuss how novel technologies and reworked translation concepts can create a more effective translational neuroscience. 
The contributors consider such topics as using genomics and neuroscience for better diagnostics and biomarker identification; new approaches to disease based on stem cell technology and more careful use of animal models; and greater attention to human biology and what it will take to make new therapies available for clinical use. They conclude with a conceptual roadmap for an effective and credible translational neuroscience—one informed by a disease-focused knowledge base and clinical experience.
Contributors: Tobias M. Böckers, Thomas Bourgeron, Karl Broich, Nils Brose, Bruce N. Cuthbert, Ilka Diester, Gül Dölen, Guoping Feng, Richard Frackowiak, Raquel E. Gur, Stephan Heckers, Franz Hefti, David M. Holtzman, Steven E. Hyman, Nancy Ip, Cynthia Joyce, Tobias Kaiser, Edward H. Koo, Walter J. Koroshetz, Katja S. Kroker, Robert C. Malenka, Isabelle Mansuy, Eliezer, Masliah, Yuan Mei, Andreas Meyer-Lindenberg, Lennart Mucke, Pierluigi Nicotera, Karoly Nikolich, Michael J. Owen, Menelas N. Pangalos, Alvaro Pascual-Leone, Joel S. Perlmutter, Trevor W. Robbins, Lee L. Rubin, Akira Sawa, Mareike Schnaars, Bernd Sommer, Maria Grazia Spillantini, Laura Spinney, Matthew W. State, Marius Wernig

Table of Contents

  1. The Ernst Strüngmann Forum
  2. Preface
  3. 1. Introduction

    Karoly Nikolich and Steven E. Hyman

  4. 2. What Do We Know about Early Onset Neurodevelopmental Disorders?

    Thomas Bourgeron

  5. 3. Psychotic Disorders and the Neurodevelopmental Continuum

    Michael J. Owen

  6. 4. Neurodevelopmental Disorders: What Is to Be Done?

    Stephan Heckers, Steven E. Hyman, Thomas Bourgeron, Bruce N. Cuthbert, Raquel E. Gur, Cynthia Joyce, Andreas Meyer-Lindenberg, Michael J. Owen, and Matthew W. State

  7. 5. Neurodegenerative Diseases: Where Are We Not Looking for Answers?

    Walter J. Koroshetz and Lennart Mucke

  8. 6. Preclinical and Clinical Understanding: Major Gaps in Our Understanding and Capabilities

    Edward H. Koo

  9. 7. Neurodegenerative Diseases: What Is to Be Done?

    David M. Holtzman, Karoly Nikolich, Menelas N. Pangalos, Karl Broich, Nancy Y. Ip, Edward H. Koo, Walter J. Koroshetz, Eliezer Masliah, Lennart Mucke, Pierluigi Nicotera, Mareike Schnaars, and Maria Grazia Spillantini

  10. 8. How Might We Get from Genes to Circuits to Disease?

    Tobias Kaiser, Yuan Mei, and Guoping Feng

  11. 9. How Do We Define and Modulate Circuits in Animals That Are Relevant to Pathophysiology in Humans?

    Joel S. Perlmutter

  12. 10. Pathophysiological Toolkit: Genes to Circuits

    Gül Dölen, Robert C. Malenka, Joel S. Perlmutter, Nils Brose, Richard Frackowiak, Bruce N. Cuthbert, Ilka Diester, Isabelle Mansuy, Katja S. Kroker, Tobias M. Boeckers, Alvaro Pascual-Leone, Guoping Feng

  13. 11. Using a Stem Cell-Based Approach to Model Neurodegenerative Disease: Where Do We Stand?

    Lee L. Rubin

  14. 12. From Rodent Behavioral Models to Human Disorders

    Trevor W. Robbins

  15. 13. Bridging the Gap between Patients and Models

    Ilka Diester, Franz Hefti, Isabelle Mansuy, Alvaro Pascual-Leone, Trevor W. Robbins, Lee L. Rubin, Akira Sawa, Marius Wernig, Gül Dölen, Steven E. Hyman, Lennart Mucke, Karoly Nikolich, and Bernd Sommer

  16. 14. The Revolution Has Begun

    Steven E. Hyman and Karoly Nikolich

  17. Bibliography
  18. Subject Index
  19. Further Titles in the Strüngmann Forum Report Series